Hikma Pharmaceuticals Share Discussion Threads

[mrthomas] 20/3/2017 11:45

I buy again if goes below 20 the question then at what price think that 18 be nice but glad i sold out on results day.

[fez77] 20/3/2017 09:56

Yeah - I just bought again! Fingers crossed!!!!!

[fez77] 20/3/2017 09:53

Hi FP - yes it is dipping. I am presently deciding whether to add......

Some conflicting broker forecasts and press views. Peel Hunt says Buy and estimates 2630 while HSBC says Reduce and estimates 1800. Quite a wide divergence!!

Ex-div on 6 April and I suspect there will be support before then. A difficult decision - perhaps the Directors will show their hand again??

British Bulls latest recommendation is to Buy:- "Our system’s recommendation today is to BUY. The BULLISH STOP LOSS pattern finally received a confirmation because the prices crossed above the Stop Loss level which was at 2,154.0000, and our valid average buying price stands now at 2,157.0000. The previous SELL signal was issued on 14/03/2017, 3 days ago, when the stock price was 2,126.0000. Since then HIK.L has risen by +1.46%.Market Outlook A rally after a bear setup can occasionally turn into an explosive long trade. We may be on the verge of catching one of them. There is now a strong positive sentiment in the market despite the absence of a bullish pattern. The bullish stop loss is finally confirmed and a BUY signal is generated. Market wants to reward the bulls. It may be now the right time to be part of this boost and bullish market sentiment by joining the growing bullish crowd."

[flyposter] 19/3/2017 21:31

@Fezz77: Opened a SB on this on Friday when it hit -1.7% for the second time on what looked look a good entry point on the rise then pullback after results, liking the tip... tomorrow should bode well, if it dips tomorrow (stranger things have happened) I will add.

[fez77] 18/3/2017 17:43

Great news!

[flyposter] 18/3/2017 17:24

Tipped in The Times today, share of the week.

[fez77] 17/3/2017 12:10

JP Morgan forecast is "neutral" - 2400

What is Barclays forecast?

[r ball] 17/3/2017 12:05

jp Morgan bearish. Barclays bullish.

[fez77] 17/3/2017 11:52

Big difference between HSBC forecast - 1800, and Peel Hunt forecast - 2630.

Others at 2340, 2400 and 2500.

I'd be confident/happy with 2300.

[fez77] 17/3/2017 11:46

Joel - no idea how dip occurred but price seems to have recovered somewhat. Odd things can happen between 8 and 8.30!!

Shardview - nice to be back in here again! Hope its all worthwhile.....

Broadwood - are you a long term holder? Any views on future prospects?

[joel erickson] 17/3/2017 11:28

Why was there such a big dip in the morning?

[broadwood] 15/3/2017 14:49

Hikma Pharmaceuticals provided a tonic for the main share index on Wednesday, with shares in the company up 7% after it reported lower profits but better sales and hiked the dividend.
On revenue up 39% to $1.95bn over the calendar year, the FTSE 100 drug maker generated statutory operating profits of $302m, which were down 21% on the previous year, though excluding exceptional items like acquisition costs, goodwill amortisation and inventory adjustments, core operating profits were up 2% to $419m.

Profits before tax fell 34% to $210m but core profits were boosted by strong growth in injectables and branded drugs, which was offset by a decline at the generics business as it integrated last February's $1.7bn acquisition of specialty generics company West-Ward Columbus and more than doubled its investment in research and development across the group.

[mrthomas] 15/3/2017 10:44

Sold out this morning did well as only held it for 5 months rather take the cash and come latter if goes down

[broadwood] 15/3/2017 09:54

Hikma Pharmaceuticals Plc using EPIC/TICKER code LON:HIK has had its stock rating noted as ‘Reiterates217; with the recommendation being set at ‘BUY’ this morning by analysts at Cantor Fitzgerald. Hikma Pharmaceuticals Plc are listed in the Health Care sector within UK Main Market. Cantor Fitzgerald have set a target price of 2500 GBX on its stock. This now indicates the analyst believes there is a possible upside of 14.7% from the opening price of 2180 GBX. Over the last 30 and 90 trading days the company share price has increased 205 points and increased 450 points respectively

[r ball] 15/3/2017 08:00

Oh. There's the answer.

[r ball] 15/3/2017 07:55

Weak warning on R&D spend. Not sure how this one will open.

[broadwood] 15/3/2017 07:29

- Hikma Pharmaceuticals saw strong growth in revenue and core operating profit in constant currency in 2016 after significant strategic progress.

Group revenue of $1,950 million was up 35% and up 39% in constant currency and group core operating profit of $419 million was up 2% and up 14% in constant currency, reflecting strong growth in Injectables and Branded profitability, partially offset by a lower contribution from the Generics business and a step-up in R&D investment across the group to support sustainable growth.

Group reported operating profit of $302 million ws down 21% and down 9% in constant currency, reflecting a significant increase in intangible amortisation and exceptional items in 2016.

Group core basic earnings per share of 118.5 cents, fell 18% and fell 5% in constant currency following the issuance of 40 million additional shares in February 2016 in relation to the West-Ward Columbus acquisition.

The proposed final dividend of 22 cents per share, and full year dividend of 33 cents per share, up from 32 cents per share for the full year in 2015.

Hikma said group revenue in 2017 was expected to be around $2.2 billion in constant currency.

Chairman and chief executive Said Darwazah said: "We made significant strategic progress in 2016. The acquisition of West-Ward Columbus is transforming our Generics business and the Group as a whole.

"This is our largest acquisition to date and the integration process has been both challenging and exciting.

"We expect the Generics business to achieve significant growth in revenue and profitability in the coming years as we focus on pipeline execution and portfolio optimisation.

"Our global Injectables business delivered excellent growth in revenue and operating profit in 2016, at the same time as we more than doubled our R&D investment to underpin the long-term growth potential for this business.

"In the MENA, our reported results were impacted by the devaluation of the Egyptian pound in November 2016. However, our strategic focus on higher value products, combined with tight cost control, drove significant growth in operating profit in constant currency and a meaningful margin expansion.

"Our business today is stronger than ever.

"We are well positioned across our markets, with a large and differentiated portfolio and pipeline and we are confident in the future prospects of the Group."

[karateboy] 14/3/2017 20:07

Good luck for tomorrow.

[mrthomas] 13/3/2017 08:39

Thanks for that not sure to sell and take gains or hold on. Have one more day to think on it this year had more down on results than up

[suetballs] 12/3/2017 21:07

Oops Wednesday not Tuesday.
Suet

[suetballs] 12/3/2017 21:04

Final results on Tuesday - fingers crossed.

Suet

[karateboy] 06/3/2017 17:03

Good day in a down market.

[karateboy] 03/3/2017 16:40

Well it is not all that bad! Somebody at close has to pay 6p premium to buy 180000 shares.